BridgeBio Pharma BBIO Operating margin
Operating margin at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Based on trailing twelve months.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating margin?
- BridgeBio Pharma (BBIO) reported operating margin of -90.5% in Q1 2026.
- How has BridgeBio Pharma's operating margin changed year-over-year?
- BridgeBio Pharma's operating margin increased by 83.5% year-over-year, from -547.6% to -90.5%.
- What is the long-term trend for BridgeBio Pharma's operating margin?
- Over 4 years (2021 to 2025), BridgeBio Pharma's operating margin has grown at a -40.4% compound annual growth rate (CAGR), from -827.1% to -104.2%.
- What does operating margin mean?
- The profit left from core operations for every dollar of sales, before interest and taxes.
- How do you interpret operating margin?
- Expanding operating margin shows operating leverage — revenue growing faster than the cost base. Compression points to rising overhead, pricing pressure, or investment ahead of revenue.
- How does operating margin compare across companies?
- Strong cross-company signal within a sector. Capital-light businesses sustain higher operating margins than capital-intensive ones.